Boston Scientific Corporation
today announced it has initiated a controlled launch of the ACURATE neo2
™ Aortic Valve System in Europe. This next-generation transcatheter aortic valve implantation (TAVI) technology is a new platform designed with a number of features to improve upon the clinical performance of the original ACURATE neo
platform. Compared to the previous generation device, the ACURATE neo2
valve system also has an expanded indication for patients with aortic stenosis – with no specified age or risk level – who are considered appropriate candidates for the therapy by their heart team, including a cardiac surgeon.